11095 Flintkote Avenue
163 articles with Ignyta Inc
Mainstay Medical Announces the Appointment of Matthew Onaitis as Chief Financial Officer
Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces the appointment of Matthew Onaitis as Chief Financial Officer, effective August 20, 2018.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.
Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
The company intends to initiate the TITAN study, a first-in-human study of RXDX-106 in patients with locally advanced or metastatic solid tumors.
Roche got in some last-minute Christmas shopping, shelling out $1.7B for San Diego's Ignyta.
Ignyta Reports Granting of Inducement Awards - Nov. 16, 2017
The awards were made on November 15, 2017, under Ignyta’s 2017 Employment Inducement Equity Incentive Award Plan.
Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results
For the third quarter of 2017, net loss was $28.6 million, or $0.51 per share, compared with $23.3 million, or $0.56 per share, for the third quarter of 2016.
Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) Meeting
Ignyta today announced new preclinical data for RXDX-106 - a novel immunomodulatory agent that demonstrated potent anti-tumor activity, alone and in combination with checkpoint inhibitors, by modulating the tumor microenvironment (TME) through TYRO3, AXL, and MER (TAM) receptor tyrosine kinase (RTK) inhibition.
Ignyta Announces Pricing of Public Offering of Common Stock of 10 Million Share
Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of 10.0 million shares of its common stock at a price to the public of $16.00 per share.
Ignyta Announces Proposed Public Offering Of Common Stock Of $125,000,000
Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock.
The good news led Ignyta's stock to jump about five percent before settling down.
Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors
Ignyta, Inc. today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation for entrectinib in the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapy.
Ignyta Issued Four Inducement Awards
Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, announced today that it has issued four inducement awards to new non-executive employees.
Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting
Ignyta Announces Updated Data On Entrectinib In ROS1 NSCLC To Be Presented At The IASLC 18th World Conference On Lung Cancer
Ignyta Reports Granting Of Inducement Awards
Ignyta Provides Update On Entrectinib And RXDX-105 At The ESMO 2017 Congress
Ignyta Announces Presentation Of New Phase IB Clinical Data On RXDX-105 In RET Fusion-Positive NSCLC At ESMO 2017 Congress
Ignyta Provides Regulatory Update On Entrectinib ROS1 Lung Cancer Development Program
Ignyta To Host Conference Call And Webcast On Entrectinib ROS1 Lung Cancer Update On September 6, 2017
Ignyta Announces Second Quarter 2017 Company Highlights And Financial Results